PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: ECON Corporate Services /™

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Smallpox Vaccine Development Agreement - MDM Group, Inc. (OTC.PK: MDDM) advises that its Biodefense Division has entered into agreement with AvaxisBio for the development of a smallpox vaccine designed for safe and effective public immunization to counter bioterrorism.
Smallpox Vaccine Development Agreement


NewswireToday - /newswire/ - Santa Clara, CA, United States, 2005/08/09 - MDM Group, Inc. (OTC.PK: MDDM) advises that its Biodefense Division has entered into agreement with AvaxisBio for the development of a smallpox vaccine designed for safe and effective public immunization to counter bioterrorism..

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


AvaxisBio is developing a vaccine by rational design, made from small peptide molecules based on selected portions of the Variola virus genome selected for optimal effects on the human immune system.

Smallpox is a top priority on the bioterrorism threat list. Since routine vaccinations stopped in 1980 and vaccination offers immunity for only seven to ten years, the world is in effect a virgin population, highly susceptible to reintroduction of the virus. Although the official repositories of the virus are maintained under high security in the United States and Russia, there is concern that terrorists may have access to certain smallpox virus and could use it as a weapon. If this happened, a large percentage of the population could become seriously ill as smallpox is highly contagious and virulent. As many as 30% of those infected could die as there is no known cure -- and if the hemorrhagic or flat smallpox variants were to be used the death rates would be much higher, 95-99%.

Currently available smallpox vaccines use modified live Vaccinia virus that are costly and time intensive in their application. As an indication, to vaccinate just a million people per day, using current methods and immunization process, would require about 35,000 medical teams as well as the infrastructure to support the initiative. Further, current vaccines are also not considered safe for use in certain segments of the population, especially those with skin diseases, immune disorders, HIV, and pregnant or lactating mothers. In addition, the FDA requires a "Black Box" (serious danger) warning on a large proportion of the currently available doses of smallpox vaccine due to concerns about occurrence of heart toxicity called acute myopericarditis in healthy individuals.

In early 2003, the U.S. government decided to vaccinate 500,000 civilian healthcare workers who would be responsible for the vaccination of the general population if necessary. By April 13, 2003, the Centers for Disease Control reported 86 potentially with serious side effects, including several deaths and several dozen cases of myocarditis -- consequently only just 32,644 healthcare workers volunteered to be vaccinated. Vaccine safety is of primary concern.

For smallpox vaccine to be available to the entire population in the event of an outbreak, MDM Group and AvaxisBio are targeting a greatly improved product and vaccination process. Both are clearly needed should such a threat materialize.

AvaxisBio Corporation was incorporated in the state of Delaware on November 8, 2004. Based on the Business Plan developed by Dr. Amir Maksyutov, senior technical director and inventor in cooperation with the US Department of State BII program (BioIndustry Initiative), AvaxisBio has attracted significant potential investment interest in the company. AvaxisBio is focused on commercializing the Maksyutov Antigenic Peptide technology platform, a method for designing vaccines that takes into account the genetic variability of pathogens that cause AIDS, Hepatitis C, and Influenza. BII enabled the commercialization of this platform through a strategic PCT (Patent Convention Treaty) filing after the early-stage discovery work was funded by BTEP (Biotechnology Engagement Program).

AvaxisBio has developed a computerized method that allows for selection of the specific regions within viral proteins that will cause a desirable immune effect against smallpox, while ruling out those regions which might cause autoimmune or other side effects. This method, based on original antigenic similarity matrix, takes into account small changes in the amino acid building block sequence of the protein regions and whether they do or do not affect the safety or efficacy of the vaccine component.

MDM Vice President, Ed Stephen, has indicated that the new vaccine is expected to be safe in all population segments as well as be effective against all strains of pox viruses by the nature of the component selection process that is proprietary to AvaxisBio.

Under the terms of the AvaxisBio agreement, MDM Group will fund certain ongoing expenses during a due diligence period, after which MDM will acquire a 50% interest in a joint company that will be newly-formed for the purpose of developing and testing smallpox vaccines, in exchange for $0.5 million of initial seed capital and other non-monetary contributions to support on-going research activities.

MDM Group's Biodefense Division is focused on discovery of and rapid development of vaccines and other countermeasures to support the Homeland Defense requirements of the United States government and its citizens as well as those in other countries.

MDM Group's business interests are focused on the Security, Biodefense and Homeland Security industries.

Safe Harbor Statement

The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.

Source: MDM Group, Inc.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: ECON Corporate Services /™


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

Smallpox Vaccine Development Agreement

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Publisher Contact: Trevor Ruehs 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any ECON Corporate Services /™ securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From ECON Corporate Services /™ / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business



Visit  RightITnow Ltd

  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (